Protagonist Therapeutics Reports First Quarter 2019 Financial Results

Wednesday, May 8, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

-- PTG-200 collaboration agreement with Janssen Biotech expanded to include second generation oral IL-23 receptor antagonists; expanded agreement triggers $25 million milestone payment to Protagonist --

PROTAGONIST THERAPEUTICS, INC.

Selected Condensed Consolidated Balance Sheet Data

(In thousands)

March 31,

December 31,

2019

2018

Consolidated Balance Sheet Data:

Cash, cash equivalents and available-for-sale securities

$

112,546

$

128,853

Working capital

$

98,496

$

111,345

Total assets

$

132,248

$

139,472

Deferred revenue – related party

$

7,001

$

8,223

Accumulated deficit

$

(154,577))

$

(140,474))

Total stockholders' equity

$

100,825

$

112,515



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store